Head to Head Review: Windtree Therapeutics (NASDAQ:WINT) versus Trillium Therapeutics (TRIL)

Windtree Therapeutics (NASDAQ: WINT) and Trillium Therapeutics (NASDAQ:TRIL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Volatility and Risk

Windtree Therapeutics has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.

Insider & Institutional Ownership

36.8% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of Trillium Therapeutics shares are owned by institutional investors. 1.3% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Windtree Therapeutics and Trillium Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Windtree Therapeutics -588.67% N/A -308.95%
Trillium Therapeutics N/A -178.08% -61.40%

Earnings and Valuation

This table compares Windtree Therapeutics and Trillium Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Windtree Therapeutics $3.23 million 0.87 -$28.34 million ($5.25) -0.04
Trillium Therapeutics N/A N/A -$28.62 million ($3.73) -1.97

Windtree Therapeutics has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Windtree Therapeutics and Trillium Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics 0 1 1 0 2.50
Trillium Therapeutics 0 0 5 0 3.00

Windtree Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 3,900.00%. Trillium Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 104.08%. Given Windtree Therapeutics’ higher probable upside, equities analysts plainly believe Windtree Therapeutics is more favorable than Trillium Therapeutics.

About Windtree Therapeutics

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

About Trillium Therapeutics

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Receive News & Ratings for Windtree Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply